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160Objective:We sought to determine the value of preoperative left ventricular function and cardiopulmonary by-
pass parameters in the prediction of left ventricular assist device implantation after repair of anomalous left
coronary artery from the pulmonary artery.
Methods:Multivariate logistic regression was performed to identify a predictive model for postrepair left ven-
tricular assist device implantation using the records of 27 patients who underwent direct aortic implantation of
anomalous left coronary artery from the pulmonary artery from 1994 to 2011.
Results: Seven patients required left ventricular assist device implantation. Patients in group 1 (n ¼ 20) were
successfully weaned from cardiopulmonary bypass. Patients in group 2 (n ¼ 7) required left ventricular assist
device as a bridge to recovery. The 2 groups were similar in age, weight, and body surface area. Six of the 7
patients (85.7%) who required left ventricular assist device survived to hospital discharge. Hospital mortality
was 3.7%. In the univariate model, fractional shortening, ejection fraction, and aortic crossclamp time were sig-
nificantly associated with left ventricular assist device implantation (P ¼ .026, .035, .031, respectively). In the
multivariate analysis, the aortic crossclamp time was the only significant independent predictor of left ventric-
ular assist device implantation. Aortic crossclamp time and fractional shortening together accounted for 80.9%
(P<.001) of the variability in left ventricular assist device implantation and constituted the best predictive
model: All patients requiring postrepair left ventricular assist device implantation had a fractional shortening
less than 20% and an aortic crossclamp time greater than 56 minutes.
Conclusions: The fractional shortening and aortic crossclamp time together predict 80.9% of the variability in
postrepair left ventricular assist device implantation after repair of anomalous left coronary artery from the pul-
monary artery. When preoperative left ventricular dysfunction is severe (fractional shortening<20%), an aortic
crossclamp time greater than 56 minutes is associated with a substantial risk of left ventricular assist device im-
plantation after repair of anomalous left coronary artery from the pulmonary artery. (J Thorac Cardiovasc Surg
2012;144:160-5)Chronic left ventricular (LV) ischemia, the primary physio-
logic derangement in anomalous left coronary artery from
the pulmonary artery (ALCAPA), leads to depression of
LV systolic function and is a significant surgical risk. LV
systolic dysfunction in such patients is characterized by
a depression in the contractile indices of fractional shorten-
ing (FS) and ejection fraction (EF). Accompanying these
changes, increased LVend-diastolic dimension and varying
degrees of mitral regurgitation (MR) are found. Severe is-
chemic LV dysfunction is common in ALCAPA, being
present in 29 of 31 children undergoing primary repair
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The Journal of Thoracic and Cardiovascular Surgcardiopulmonary bypass (CPB) required for surgical repair
may further aggravate LV dysfunction in the immediate
postoperative period. The creation of a dual coronary blood
supply often results in substantial improvement in contrac-
tile function after ALCAPA repair with no need for postop-
erative mechanical circulatory support (MCS). In some
children, however, profound postoperative contractile dys-
function requiring potentially injurious doses of inotropes
or failure to wean from CPB occurs despite adequate repair.
MCS in the form of a left ventricular assist device (LVAD)
is required as a bridge to recovery in such patients.
Several studies have documented the successful use of an
LVAD as a bridge to recovery in patients with ALCAPA,1-3
but predicting LVAD implantation in patients undergoing
repair has not been well defined. Prediction is important
as part of preoperative planning and parental counseling.
Furthermore, such prediction may provide therapeutic
targets to facilitate weaning of such patients from CPB.
Nasseri and colleagues4 recently investigated the predictors
of LVAD requirements after ALCAPA repair, but their
study was limited to infants (aged 12 months). In their re-
port, the LV end-diastolic dimension was the most signifi-
cant indicator of postrepair LVAD requirement.4 Azakieery c July 2012
Abbreviations and Acronyms
ALCAPA ¼ anomalous left coronary artery from
the pulmonary artery
ATP ¼ adenosine triphosphate
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
ECMO ¼ extracorporeal membrane
oxygenation
EF ¼ ejection fraction
FS ¼ fractional shortening
LV ¼ left ventricular
LVAD ¼ left ventricular assist device
MCS ¼ mechanical circulatory support
MR ¼ mitral regurgitation
ROC ¼ receiver operating characteristic
XCT ¼ aortic crossclamp time
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Dand coworkers5 studied patients up to 31 years of age under-
going ALCAPA repair and reported that the median preop-
erative EF was significantly lower for patients who had
extracorporeal membrane oxygenation (ECMO) compared
with those who did not (10% vs 40%; P ¼ .01). The
mean preoperative predicted LV end-diastolic diameter
was higher in the ECMO group (1.74 vs 1.34 cm;
P ¼ .027).5 Regression analyses were not performed in
these studies.
The present study was prompted by our recent experience
with a 32-month-old patient with ALCAPA and severe LV
dysfunction who could not be weaned from CPB. With
the use of logistic regression analysis, we sought to deter-
mine the predictive value of preoperative LV function and
CPB conditions on LVAD implantation after ALCAPA re-
pair in infants and children during our 17-year experience.PATIENTS AND METHODS
Current repair of ALCAPA involves direct aortic implantation with car-
dioplegia delivered into the aorta and pulmonary artery to ensure adequate
protection of both coronary territories. We included only patients who un-
derwent direct aortic implantation as a means of revascularization of
ALCAPA in the study period. Three patients (early in the experience)
were excluded from the analysis for the following reasons: Takeuchi pro-
cedure (1), saphenous vein grafting of the left coronary artery (1), and car-
dioplegia delivery to the aortic root only (1).
We performed a retrospective analysis of all consecutive patients who
underwent direct aortic implantation of ALCAPA by our group from Jan-
uary 1994 to June 2011. The diagnosis of ALCAPAwas established on the
basis of typical electrocardiography and findings on transthoracic echocar-
diogram. Coronary angiography was performed in doubtful cases (13 pa-
tients, 46.4%). The anomalous left coronary artery took origin from the
right pulmonary artery in 1 patient but from the root of the main pulmonary
artery in all other patients. The LV function parameters selected for analy-
sis included the FS, EF, LVend-diastolic dimension, and MR severity. The
LV end-diastolic dimension was indexed to the body surface area for the
analysis. The severity of MR was graded as grade 1 (nil or mild) or 2The Journal of Thoracic and Ca(moderate or severe). CPB was assessed using the aortic crossclamp time
(XCT) and total CPB time. The XCT measured represents that for a single
crossclamp during the initial ALCAPA repair.
A total of 27 patients qualified for inclusion in the study. Patients were
divided into 2 groups. Group 1 (n ¼ 20) included patients who were suc-
cessfully separated from CPB after ALCAPA repair. Group 2 (n ¼ 7) in-
cluded patients who required LVAD because of failure to separate from
CPB after ALCAPA repair.
Failure to wean from CPB after repair was defined as mean arterial pres-
sure less than 45 mm Hg and left atrial pressure greater than 16 mmHg de-
spite the use of high-dose multidrug inotropic support and prolonged
reperfusion.
Surgical Technique
All operations were performed through a median sternotomy with can-
nulation of the distal ascending aorta and a single venous drain. The tech-
nique of reimplantation was essentially similar in all patients, but the
performance of the procedures by 4 different surgeons over a period of
17 years introduced some variability in the crossclamp and total bypass
times. Our technique involves institution of hypothermic bypass (25C)
and cold crystalloid (20 patients) (St Thomas Solution; Abbott Laborato-
ries, Abbott Park, Ill) or cold blood cardioplegia (7 patients) infused si-
multaneously into the roots of the ascending aorta and main pulmonary
artery after snaring the branch pulmonary arteries. We implant the
ALCAPA into the corresponding aortic sinus to achieve minimal distor-
tion of the anastomosis (ie, where the ALCAPA was originally meant to
be). The pulmonary artery is reconstructed with autogenous pericardium
while the patient is rewarmed. One patient aged 2.7 years underwent
a Reed’s annuloplasty repair of the mitral valve for severe MR and giant
left atrium. Our technique and management of LVAD have been de-
scribed.6 The important modification in patients with ALCAPA requiring
LVAD is the insertion of an LV apical cannula for drainage to facilitate
complete decompression of the LV.
Statistical Analysis
Descriptive statistics were calculated to summarize data. Normally dis-
tributed continuous variables are reported as mean  standard deviation.
Continuous variables not normally distributed are presented as geometric
mean (95% confidence interval [CI]) or range (median). Categoric vari-
ables are summarized and presented as frequencies and percentages. Dif-
ferences in means of continuous and categoric variables were compared
between groups by independent-samples Student t test assuming equal var-
iance. Variables not normally distributed were transformed on the natural
log scale for the Student t test. Categoric variables were compared between
groups using the Pearson chi-square test.
Univariate logistic regression analysis was performed to assess associ-
ations between variables of interest and postrepair LVAD implantation. To
identify predictors of postrepair LVAD implantation, risk factors showing
statistically significant associations were further investigated using multi-
variate logistic regression. Collinearity among predictors was assumed if
the variance inflation factor was greater than 10 and a relationship between
predictor variables was known.
Receiver operating characteristic (ROC) curve analysis was used to de-
termine predictive probabilities and the highest sensitivity/specificity for
predicting postrepair LVAD implantation.
The results of logistic regression analyses are presented as odds ratios
with 95% CI. All statistical tests were 2-sided. Statistical analyses were
performed using IBM SPSS v19 (SPSS Inc, Chicago, Ill) and STATA SE
v11.2 (StataCorp LP, College Station, Tex).
RESULTS
Group 1 included 20 patients, and group 2 included 7 pa-
tients. Groups 1 and 2 showed no statistically significantrdiovascular Surgery c Volume 144, Number 1 161
TABLE 1. Whole group data
Group 1 Group 2 P value
No. 20 7
Age (mo)* 5.11 (2.47–10.57) 4.23 (1.47–12.14) .78
Weight (kg)* 6.25 (4.83–8.07) 5.66 (3.71–8.65) .67
BSA (m2)* 0.32 (0.26–0.39) 0.31 (0.22–0.43) .83
FS (%) 20.7  6.4 13.1  5.9 .01
EF (%) 41.3  12.2 28.1  11.4 .02
LV end-diastolic dimension index (mm/m2) 129.1  43.6 98.6  55.0 .12
MR grade (grade 2) 10 (50%) 5 (71.4%) .47
Cardioplegia (blood) 4 (20%) 3 (43%) .24
XCT (min)* 50.93 (44.74–57.98) 77.53 (53.30–112.78) .005
CPB time (min)* 82.21 (74.92–90.22) 163.27 (107.35–248.33) <.001
BSA, Body surface area; FS, fractional shortening; EF, ejection fraction; LV, left ventricular; MR, mitral regurgitation; XCT, aortic crossclamp time; CPB, cardiopulmonary
bypass. *Variables not normally distributed (presented as geometric means, 95% CI).
TABLE 2. Univariate logistic regression analysis of left ventricular
assist device implantation on selected variables
Variable OR (95% CI) P value R2 (Nagelkerke)
FS (%) 0.81 (0.67–0.98) .026 0.342
EF (%) 0.89 (0.81–0.99) .035 0.328
LV end-diastolic
dimension index
(mm/m2)
1.00 (0.98–1.03) .79 0.00
Congenital Heart Disease Edwin et al
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Ddifferences in terms of age, weight, and body surface area
(Table 1). Apart from infants, the total patient cohort in-
cluded 4 older children aged 2.4 to 17 years (median 3.9
years) with an FS of 19.5% to 33.0% (median 20.5%);
an LVAD was required in 1 of these patients.
LV function between the 2 groups (Table 1) differed sig-
nificantly in terms of FS (20.7%  6.4% vs 13.1% 
5.9%, P ¼ .01) and EF (41.3%  12.2% vs 28.1% 
11.4%, P ¼ .02). Fourteen patients had an FS less than
20%, 7 of whom required postrepair LVAD. The LV
end-diastolic dimension (indexed to the body surface
area), MR severity, and vehicle of cardioplegia showed
no significant difference between the 2 groups (Table 1).
As reflected in the total bypass time (Table 1), significantly
prolonged reperfusion was allowed in group 2 to encour-
age separation from CPB. The prolonged bypass time in
group 2 mainly resulted from attempted weaning from by-
pass and time spent implanting the LVAD; when the differ-
ences in XCT were accounted for, the initial bypass time
during the actual repair was not significantly different be-
tween the 2 groups.
Seven patients required postrepair LVAD; 6 were suc-
cessfully bridged to recovery and 1 died (3.7% hospital
mortality). The patient who did not survive was the
only one to require ECMO because of postoperative re-
spiratory failure from pulmonary infection. He died of in-
tractable pulmonary sepsis after 228 hours of ECMO.
The mean duration of LVAD support for the 7 patients
was 84  66 hours. One major complication was encoun-
tered during LVAD support–aortic cannula thrombosis
necessitating termination of LVAD after 60 hours. The
patient survived termination of mechanical support
uneventfully.XCT (min) 1.09 (1.01–1.18) .031 0.442
Age (mo) 0.99 (0.94–1.04) .59 0.032
Weight (kg) 0.95 (0.78–1.16) .64 0.018
BSA (m2) 0.42 (0.00–49.54) .78 0.004
OR, Odds ratio; FS, fractional shortening; EF, ejection fraction; LV, left ventricular;
XCT, aortic crossclamp time; BSA, body surface area.Logistic Regression Analysis
After univariate logistic regression analysis, 3 indepen-
dent variables (FS, EF, and XCT) were considered the
most likely predictors (Table 2). The variance inflation162 The Journal of Thoracic and Cardiovascular Surgfactor for the 3 variables was 31.7 for FS and EF and 1.0
for XCT. In a linear regression model, the relationship be-
tween the EF and FS was determined to be
EF ¼ 1:85 FSþ3:34R2 ¼ 0:965; P ¼ :01:
On this basis and our preference for using FS as a measure
of LV function, we excluded EF from the multivariate anal-
ysis of predictors noting that its predictive power will be ac-
counted for almost entirely by the FS.
The FS and XCTwere significantly associated with post-
repair LVAD implantation (P¼ .026 and .031, respectively)
in the univariate model (Table 2).
In the multivariate regression analysis (Table 3), only the
XCT reached independent predictor status (P ¼ .051). The
XCTalone accounted for a modest 44.2% of the proportion
of variability in LVAD implantation (Table 2), but taken to-
gether with the FS in the multivariate analysis (Table 3), the
explanatory value of the model improved significantly to
80.9% (R2 ¼ 0.809, c2 ¼ 21.67, degrees of freedom ¼ 2,
P<.001).
Receiver Operating Characteristic Analyses
By having determined that the best predictive model de-
pended on a combination of the XCT and FS, ROC curveery c July 2012
TABLE 3. Multivariate logistic regression of left ventricular assist
device on fractional shortening and aortic crossclamp time
Variable OR (95% CI) P value
XCT (min) 1.19 (1.00–1.41) .051
FS (%) 0.54 (0.26–1.12) .097
R2 for XCTand FS together¼ 0.0809 (P<.001). OR,Odds ratio; FS, fractional short-
ening; XCT, aortic crossclamp time.
FIGURE 1. Influence of XCTon predicted probability of LVAD in severe
LV dysfunction. LV, Left ventricular; LVAD, left ventricular assist device;
XCT, aortic crossclamp time.
Edwin et al Congenital Heart Diseaseanalysis was conducted to determine the threshold values
for XCT and FS that optimize sensitivity and specificity
for the prediction. Because the FS varied inversely with
the probability of LVAD implantation, each FS observation
was transformed to FS’, where FS’ ¼ 100%FS. The FS’
was then plotted against the LVAD requirement for the ROC
curve analysis.
The ROC curve analysis showed an FS’ value of 80.25%
(or FS of 19.75%, approximated to 20%) as the threshold
for a sensitivity of 100% and a specificity of 55%. The
threshold XCT was 56 minutes (100% sensitivity, 55%
specificity).
On the basis of these thresholds, the predicted probability
of LVAD implantation for patients with severe LV dysfunc-
tion (FS<20%) increased from 16% at an XCTof 56 min-
utes to 86% at an XCT of 59 minutes (Figure 1).C
H
DDISCUSSION
Predicting Left Ventricular Assist Device
Implantation After Anomalous Left Coronary Artery
From the Pulmonary Artery Repair
Previous authors4,5 have investigated predictors of post-
repair LVAD implantation in patients with ALCAPA by as-
sessing statistically significant differences in the mean
values of predictors between patients who did and did not
requireMCS; logistic regression analysis was not used. Fur-
thermore, the contribution of intraoperative events to the
postoperative outcome was not investigated. Both of these
concerns have been addressed in the current study seeking
to identify preoperative and intraoperative predictors. In
keeping with their findings,4,5 our study demonstrates the
importance of preoperative LV function in predicting the
need for MCS after ALCAPA repair. But, unlike the
previous studies,4,5 the current study did not demonstrate
the predictive value of the LV end-diastolic dimension;
LV end-diastolic pressure measurements were not uni-
formly available in our patient cohort to allow analysis.
As shown in the present study, strong collinearity exists be-
tween the FS and EF such that after accounting for 1 of
these parameters, no additional predictive power is gained
by the inclusion of the other in the predictive model.
The XCT emerged as the most significant independent
predictor of LVAD implantation (odds ratio, 1.19; 95%
CI, 1.00–1.41; P ¼ .05) with a threshold value of 56 min-
utes. For the whole group, the XCT alone explains 44.2%The Journal of Thoracic and Caof the variability in LVAD requirement. However, the pre-
dictive value of the XCT is most important when taken to-
gether with the FS. Both together accounted for 80.9% of
the variability in LVAD implantation (P<.001). All patients
who required postrepair LVAD had an FS less than 20%;
thus, we consider FS less than 20% as severe LV
dysfunction.Severe Left Ventricular Dysfunction and
Vulnerability to Ischemia
Without the use of LVAD, patients with ALCAPA with
severe LV dysfunction (FS< 20%) are at increased risk
for perioperative mortality. Vouhe and coworkers7 docu-
mented that the severity of preoperative LV dysfunction
was the only incremental risk factor for mortality in 31 con-
secutive children with ALCAPA undergoing direct aortic
implantation without an associated procedure: 31%mortal-
ity rate among patients with FS less than 20% versus 0%
among patients with FS 20% or greater (P ¼ .03). In 39
consecutive patients undergoing dual coronary repair for
ALCAPA, Lambert and coworkers8 found that total mortal-
ity was related only to the preoperative FS: 12% versus
24.8% (P<.05). Lange’s group9 recently documented es-
sentially similar findings. Our study is in agreement with
the work of these investigators7-9 that an FS less than
20% in ALCAPA constitutes severe LV compromise and
that substantial operative mortality may result without
LVAD implantation.
From our results, the XCT best distinguishes those with
severe LV dysfunction who ultimately require postrepair
LVAD; the predicted probability of LVAD requirement in
this group was sensitive to increases in XCT of more thanrdiovascular Surgery c Volume 144, Number 1 163
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of 59 minutes (Figure 1). It seems that preoperative severe
LV dysfunction in ALCAPA predisposes to the accelerated
decline in contractile function beyond an ischemic time of
56 minutes. The XCT should be kept at less than 56 minutes
in the repair of ALCAPAwith severe LV dysfunction. Those
without severe LV dysfunction do not seem to exhibit such
a vulnerability to ischemia beyond 56 minutes. Modi and
coworkers10 demonstrated a significant decline in the myo-
cardial adenosine triphosphate (ATP) concentrations in both
infants and children undergoing correction of congenital
cardiac anomalies under CPB. The decline in ATP levels
was strongly determined by the XCT time. Furthermore, in-
fants and children who required a higher dose of postoper-
ative inotropic support were those with a significantly
greater degree of decline in myocardial ATP concentra-
tion.10 Intramyocardial ATP content has been shown to cor-
relate with myocardial function11; ostensibly, in ALCAPA
with severe LV dysfunction, XCTs exceeding 56 minutes
promote a critical depletion of myocardial ATP to levels
not immediately compatible with a spontaneous circulation.
Intraoperative Myocardial Management and Left
Ventricular Assist Device Requirement
The predictive value of the XCT led us to speculate that
the ischemic LV myocardium in patients with ALCAPA
has a reduced tolerance for the myocardial stunning im-
posed by XCT and reperfusion. This tolerance seems to
be critical at an XCT of 56 minutes in those with an FS
less than 20%. At this degree of depressed LV function, in-
creasing degrees of myocardial stunning, reflected in a pro-
longed XCT, crosses a threshold that makes the probability
of failure to wean from CPB and a requirement for LVAD
implantation substantial. Better intraoperative myocardial
management in terms of reducing crossclamp times and
improved protection by cardioplegia would favorably alter
this balance toward successful weaning from CPB. Backer
and coworkers12 demonstrated the favorable outcome in
terms of successful weaning from CPB by keeping the
crossclamp time short. In a series of 16 patients, these
workers achieved a mean XCT of 46  13 minutes by re-
moving the XCT after implantation of the anomalous left
coronary artery before reconstruction of the pulmonary ar-
tery.12 There was no operative mortality, and as would be
predicted from our model, none of their patients required
postrepair LVAD.
As a corollary to the effect of the XCT, we expected that
blood cardioplegia would favorably influence outcomes in
terms of LVAD requirement. Blood cardioplegia is re-
ported to offer superior myocardial protection compared
with crystalloid cardioplegia.13 It is reported to have sev-
eral benefits: enhanced oxygen-carrying capacity, active
resuscitation, avoidance of reperfusion injury, and endoge-
nous oxygen free radical scavenging among others.13 Belli164 The Journal of Thoracic and Cardiovascular Surgand coworkers14 showed that blood cardioplegia may be
advantageous in ALCAPA repair. These investigators as-
sessed outcomes in 21 infants with ALCAPA with severe
preoperative LV dysfunction (FS<15%) undergoing ana-
tomic repair under normothermic CPB using intermittent
antegrade normothermic blood cardioplegia for myocar-
dial protection. All of their patients were successfully
weaned from CPB after a mean XCTof 50  14.5 minutes;
LVAD was not necessary in any patient. There was 1
(4.7%) early death due to sudden cardiac arrest 48 hours
after successful weaning from mechanical ventilation.
Other investigators15 have speculated that a strategy using
both antegrade and retrograde blood cardioplegia, com-
bined with appropriate postoperative inotropic support,
may allow for favorable results without the need of
MCS. We could not demonstrate that blood cardioplegia
made a significant difference to outcomes in terms of
LVAD requirement. We used cold antegrade blood cardio-
plegia without terminal warm blood cardioplegic reperfu-
sion (‘‘hot shot’’) in 4 patients in group 1 and 3 patients
in group 2. We could not demonstrate any significant dif-
ference in terms of LVAD requirement between cold blood
and cold crystalloid cardioplegia. The explanation might
be that although cold blood cardioplegia by itself is supe-
rior to cold crystalloid cardioplegia, it is not as good as
cold blood cardioplegia with a hot shot.10 Seemingly,
both the method and vehicle of cardioplegia delivery influ-
ence outcomes.
Outcome of Left Ventricular Assist Device Use in
Anomalous Left Coronary Artery From the
Pulmonary Artery Repair
Depending on the preoperative severity and institutional
policy, the requirement for postoperative MCS after
ALCAPA repair ranges from 25% to 36%.12 We used
a veno-apical (right atrium and LV apex) cannulation tech-
nique with the Levitronix CentriMag (Levitronix LLC,
Waltham, Mass) system and pump flow of 120 mL/kg at
normothermia using phosphorylcholine-coated bypass cir-
cuits with the Levitronix device. In our experience, an
LVAD was required in 7 of 27 patients (26%). Compared
with the results of pediatric MCS for other indications,
the results of MCS in the setting of ALCAPA are particu-
larly encouraging.1-3,16 We were able to wean and
discharge 6 of 7 patients from MCS after ALCAPA
repair, a success rate of 85.7%.
Karl and coworkers17 reported on 115 pediatric patients
with postcardiotomy heart failure supported with a ventric-
ular assist device. The probability of weaning patients from
the ventricular assist device was 66%; the probability of
hospital discharge was 43%. Some investigators believe
the excellent outcomes of LVAD in ALCAPA justify ag-
gressive therapy regardless of the status of the LV.1 Our re-
sults would support such a management posture.ery c July 2012
Edwin et al Congenital Heart DiseaseStudy Limitations
Because this is a retrospective study, inherent limitations
of such studies also apply to this report. ALCAPA is an un-
common clinical condition, and large single-center series
are just as uncommon. The relatively small sample size
made testing of many variables in the logistic model
impossible.
No consensus exists on the guidelines for postcardiotomy
LVAD implantation in children. Different surgical teams
have variable thresholds for LVAD implantation, a phenome-
non that affects the generalizability of the study results.C
H
DCONCLUSIONS
The requirement for MCS after ALCAPA repair is best
predicted by the preoperative severity of LV dysfunction
and the duration of ischemia imposed during the repair.
When preoperative LV dysfunction is severe (FS<20%),
an XCT time greater than 56 minutes imposes a substantial
risk of failure to wean from CPB, leading to a requirement
for postoperative MCS.
The authors thank Dr Kissinger Marfo of the Korle Bu Teaching
Hospital for assistance with statistical software and literature.
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